Abstract
Objectives To establish whether there is any change in mortality associated with infection of a new variant of SARS-CoV-2, designated a Variant of Concern in December 2020 (VOC-202012/1) compared to that associated with infection with circulating SARS-CoV-2 variants.
Design Matched cohort study. Cases are matched by age, gender, ethnicity, index of multiple deprivation, lower tier local authority region, and sample date of positive specimen, and differing only by detectability of the spike protein gene using the TaqPath assay - a proxy measure of VOC-202012/1 infection.
Setting United Kingdom, community - based (Pillar 2) COVID-19 testing centres using the TaqPath assay.
Participants 54,906 pairs of participants testing positive for SARS-CoV-2 in Pillar 2 between 1st October 2020 and 29th January 2021, followed up until the 12th February 2021.
Main outcome measures Death within 28 days of first positive SARS-CoV-2 test.
Results There is a high probability that the risk of mortality is increased by infection with VOC-202012/01 (p <0.001). The mortality hazard ratio associated with infection with VOC-202012/1 compared to infection with previously circulating variants is 1.64 (95% CI 1.32 - 2.04) in patients who have tested positive for COVID-19 in the community. In this comparatively low risk group, this represents an increase from 2.5 to 4.1 deaths per 1000 detected cases.
Conclusions If this finding is generalisable to other populations, VOC-202012/1 infections have the potential to cause substantial additional mortality compared to previously circulating variants. Healthcare capacity planning, national and international control policies are all impacted by this finding, with increased mortality lending weight to the argument that further coordinated and stringent measures are justified to reduce deaths from SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: RC and KTA gratefully acknowledge the financial support of the EPSRC via grants EP/N014391/1, EP/T017856/1, and NHS England, Global Digital Exemplar programme. LDanon and KTA gratefully acknowledge the financial support of The Alan Turing Institute under the EPSRC grant EP/N510129/1. LDanon, RC and EBP are supported by MRC (MC/PC/19067). JMR acknowledges support from EPSRC (EP/N014499/1) and MRC (MR/S004793/1, MR/V028456/1). EBP was partly supported by the NIHR Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol, in partnership with Public Health England (PHE). LDanon, EBP, JMR and LDyson are further supported by MRC (MR/V038613/1) and LDanon by EPSRC EP/V051555/1. LDyson also received support through the MRC through the COVID-19 Rapid Response Rolling Call (grant number MR/V009761/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data were supplied from the SGSS database and death reports after anonymisation under strict data protection protocols agreed between the University of Exeter and Public Health England. The ethics of the use of these data for these purposes was agreed by Public Health England with the Governments SPI-M(O) / SAGE committees. The research was assessed as not needing NHS Research Ethics Committee review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated data to 12th Feb 2021. Addressed peer review comments. Further analysis on time dependence of hazards.
Data Availability
The data are available on request and appropriate data sharing agreement from Public Health England. Code for the analysis is available at doi: 10.5281/zenodo.4501299